Can immune therapy IVIG calm long COVID's autonomic storm?
NCT ID NCT06305793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether intravenous immunoglobulin (IVIG) can reduce symptoms of autonomic dysfunction—such as dizziness, rapid heartbeat, and fatigue—in people with long COVID. Two hundred participants will receive either IVIG or a placebo (saline) for 9 months, plus coordinated non-drug care. The goal is to see if IVIG improves daily function and symptom severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IVIG (intravenous immunoglobulin)
What this could lead to
If IVIG works, it could provide a treatment for autonomic symptoms like dizziness and rapid heart rate in long COVID patients.
What could go wrong
This is a Phase 2 trial with 200 participants, so results are preliminary. IVIG can cause side effects like headache, fever, or allergic reactions, and may not prove effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
All sites listed under NCT06305780
Durham, North Carolina, 27710, United States